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Tuberculosis (TB) kills more people each year than any infectious disease worldwide with
recent exception of SARS-CoV-2. Though the Bacille Calmette Guerin (BCG) vaccine
confers protection against severe extrapulmonary forms of TB, there is no licensed vaccine
for the prevention of pulmonary tuberculosis. The strongest correlate of protection against
pulmonary tuberculosis is Th1/Th17 biased cell mediated immunity. Several candidates
for TB vaccine adjuvants have shown Th1/Th17 polarizing capacity in clinical trials
including Mincle agonist trehalose dibehenate (TDB) and TLR4 agonist monophosphoryl
lipid A (MPL). Furthermore, combinatorial administration of MPL and TDB formulated in
dimethyldioctadecylammonium (DDA) liposomes has been previously reported to produce
synergistic Th1/Th17 immunity. Though this novel combination offered proof of concept
for TLR4 and Mincle combination vaccines, use of shorter chain length agonists would
afford increased stability and decreased toxicity while maintaining or improving efficacy.
Coating of Mincle ligands to silica nanoparticles (SNPs) provides an additional opportunity
to form multiple ligand-receptor interactions for increased signaling as previously
characterized in Dectin-1. Herein, we characterize several molar ratios of synthetic MPL
mimetic INI-2002 and novel TDB derivative UM-1098 delivered via A-SNPs, reporting
synergistic IL-1β production in human peripheral blood mononuclear cells and an
increased percentage of CD4+ T cells producing Th1/17 cytokines including TNF- α, IL17, and IFN-γ following combination vaccination against recombinant TB antigen M72.

ii

TABLE OF CONTENTS
CHAPTER 1: INTRODUCTION ....................................................................................... 1
Tuberculosis As a Worldwide Health Threat .................................................................. 1
Tuberculosis Pathology ................................................................................................... 2
Clinical Tuberculosis Vaccine Approaches .................................................................... 2
Recombinant Antigens for Subunit Tuberculosis Vaccines ............................................ 4
Table 1: Clinically relevant TB fusion proteins .......................................................... 5
T Cell Activation and Differentiation ............................................................................. 6
Table 2: CD4+ T Cell Subsets and Their Defining Features ....................................... 7
Figure 1: CD4+ T Cell Activation and Differentiation ............................................... 8
Innate Immune Receptors and T Cell Polarization ......................................................... 8
Figure 2: APC recognition of pathogen motifs through PRRs directs the production
of T cell polarizing cytokines ...................................................................................... 9
Toll Like Receptor 4 Agonists ........................................................................................ 9
Figure 3: TLR4 Signaling Pathways. ........................................................................ 10
Macrophage Inducible C-Type Lectin Receptor Agonists ............................................ 11
Figure 4: Mincle/MCL Signaling Pathway ............................................................... 12
Toll Like Receptor 4 Crosstalk with Macrophage Inducible C-Type Lectin Receptor 13
Adjuvant Delivery by Silica Nanoparticles ................................................................... 14
Thesis Hypothesis and Project Rationale ...................................................................... 14
CHAPTER 2: METHODOLOGY .................................................................................... 17
Preparation of Compounds ............................................................................................ 17
Preparation of Formulations .......................................................................................... 19
Table 3: Formulation Details ..................................................................................... 20
Isolation of Human PBMCs .......................................................................................... 21
Analysis of Cytokine Production .................................................................................. 21
In Vivo Experiments ..................................................................................................... 22
ELISA for anti-M72 antibody quantification. ............................................................... 22
Lymphocyte restimulation and cell-mediated immunity analysis................................. 23
Statistical Analysis ........................................................................................................ 24
CHAPTER 3: RESULTS .................................................................................................. 25
In Vitro Stimulation of Human PBMCs ........................................................................ 25
iii

Figure 5: Coating density dependent responses of UM-1098 on A-SNPs ................ 25
Table 4: Effective Concentrations in Human PBMCs............................................... 26
Figure 6: Innate cytokine production in human PBMCs ........................................... 27
Table 5: Max cytokine output in human PBMCs ...................................................... 28
Figure 7: Constant addition of 1µM UM-1098 to INI-2002 dose response in human
PBMCs....................................................................................................................... 29
Figure 8: Constant addition of 0.01µM INI-2002 to UM-1098 dose response in
human PBMCs........................................................................................................... 30
Figure 9: Constant addition of 0.05µM INI-2002 to UM-1098 dose response in
human PBMCs........................................................................................................... 31
In Vivo Vaccination of C57BL/6 Mice Against M72: Humoral Immunity .................. 31
Figure 10: In vivo study schedule and endpoints ....................................................... 32
Table 6: In vivo study conditions ............................................................................... 33
Figure 11: Post-secondary antibody titers ................................................................. 34
Figure 12. Post-tertiary antibody titers ...................................................................... 34
In Vivo Vaccination of C57BL/6 Mice Against M72: Cell-Mediated Immunity ......... 35
Figure 13: Representative T Cell Gating Strategy..................................................... 37
Figure 14: Combination vaccination increases percentage of antigen specific CD4+ T
Cells Producing Th1 Biasing Cytokines.................................................................... 38
Figure 15: Combination Vaccination Increases IL-17 and IFN-y Recall Upon
Splenocyte Restimulation .......................................................................................... 39
CHAPTER 4: DISCUSSION ............................................................................................ 40
CHAPTER 5: CONCLUSIONS ....................................................................................... 45
Summary of Findings .................................................................................................... 45
Future Directions ........................................................................................................... 45
BIBLIOGRAPHY ............................................................................................................. 47

iv

CHAPTER 1: INTRODUCTION
Tuberculosis As a Worldwide Health Threat
Tuberculosis (TB) has long remained a leading cause of death worldwide. Apart
from SARS-CoV-2, TB kills more people annually than any other communicable disease,
exceeding even human immunodeficiency virus (HIV). There were an estimated 1.5
million deaths globally due to tuberculosis in 2021. This estimate by the World Health
Organization (WHO) exceeds those of previous years due largely to disruptions in
healthcare by the SARS-CoV-2 epidemic (1). The full impact of SARS-CoV-2 related
disruptions is yet to be seen; decreased diagnosis and treatment of new and existing
infections as well as decreased rates of childhood vaccination during the pandemic threaten
global progress against TB. The poor management of tuberculosis during the pandemic has
demonstrated that the existing infrastructure and funding for tuberculosis prevention and
treatment is unreliable under strain and makes a strong argument for the necessity of an
effective vaccine.
The development of rifampicin-resistant TB (RR-TB) and multi-drug resistant TB
(MDR-TB) has further stressed the importance of proactive measures against TB. A once
curable disease, drug resistance has reduced the efficacy of antitubercular regimens;
success rates of treatment in MDR-TB and RR-TB cohorts was estimated at 59% in 2018,
an improvement from a previous estimate of 50% in 2012 (1). An estimated 5.7% of all
TB cases are diagnosed as drug resistant, though incidence of MDR-TB is
disproportionately high in Russia where rates of MDR-TB are estimated at up to 18% of
cases (2). The lengthy treatment of MDR-TB requires significant resources and exacerbates
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the heavy economic burden caused by TB, already exceeding 1% of total GDP in several
high burden countries (3).
Tuberculosis Pathology
The causative agent of TB, Mycobacterium tuberculosis (Mtb), is an acid-fast
bacterium transmitted through the inhalation of aerosolized droplets. Disease progression
is characterized by a primary infection, latent phase, and a deadly secondary infection also
called active TB (4). It’s estimated that one tenth of all infected individuals will develop
active TB (5). Pulmonary tuberculosis accounts for over 70% of all TB incidence; primary
infection in the lung is characterized by the phagocytosis of inhaled bacilli by alveolar
macrophages, followed by lysosomal escape and intracellular proliferation (6,7).
Recruitment of immune cells to surround the infected macrophages results in granuloma
formation which both prevents the dissemination of infection and creates an immune
privileged site for the bacteria, allowing for latent infections to persist for decades (6).
Active infection is achieved when the granuloma’s immune environment is disrupted
leading to tissue necrosis and eventual cavitation, freeing the bacteria into the lung and
facilitating spread (6). Extrapulmonary TB can have diverse presentations and most
commonly manifests in the skeletal system, lymph nodes, pleura, and meninges (8).
Extrapulmonary forms of TB were estimated to make up 18% of all new and relapse cases
globally in 2020 (1).
Clinical Tuberculosis Vaccine Approaches
The only licensed vaccine for prevention of TB is the Bacille-Calmette Guerin
(BCG) vaccine. BCG is composed of live attenuated Mycobacterium bovis, a relative of
Mtb, that infects the host and provokes Th1 immunity (9). Vaccination of infants with BCG

2

is strongly encouraged to prevent dangerous forms of extrapulmonary tuberculosis such as
tubercular meningitis, however BCG isn’t protective against pulmonary forms of
tuberculosis and is no longer recommended in adults (1,10). Present research aims to
develop a vaccine for the prevention of pulmonary tuberculosis.
Among whole cell TB vaccine approaches are those which aim to supplement or
improve the present BCG vaccine. Recombinant BCG vaccine VPM1002 demonstrated in
clinical trials that, through genetic modification, BCG’s efficacy and safety profiles can be
improved (11). Others have shown preclinical success in supplementing the BCG vaccine
in a prime-boost approach utilizing live attenuated Mtb vaccine MTBVAC (12). These
whole cell approaches offer advantages including strong immunogenicity and long lasting
immunity, however some drawbacks include higher risk of adverse reactions and decreased
stability (13,14). Improved safety profiles have made acellular vaccines more attractive to
patients over their cellular counterparts. The acellular pertussis vaccine was developed as
a reaction to public dissatisfaction with the adverse reactions associated with the whole cell
vaccine (14).
Acellular subunit vaccines offer superior safety and ease of mass production in
comparison to their whole cell counterparts (13,14). By using only antigens capable of
producing protective immunity against a pathogen, subunit vaccines are able to limit offtarget effects as well as provoke tailored antigen-specific responses (13,14). Thoughtfully
designed recombinant TB antigens can even combine multiple immunodominant epitopes
into one protein; recombinant antigens Ag85B-ESAT-6 and M72 are two which have
shown promising results in clinical trials (15,16). Adjuvants are necessary additions to
subunit vaccines for immunogenicity comparable to that conferred by the naturally
3

occurring pathogen associated molecular patterns (PAMPs) found in whole cell vaccines.
Adjuvants also offer a unique opportunity to direct immune bias by activating pattern
recognition receptors (PRRs) with desired downstream effects.
Understanding the correlates of protection against tuberculosis is where rational
adjuvant design begins. The strongest correlates for protective immunity against
pulmonary TB are T helper type 1 (Th1) and T helper type 17 (Th17) responses (17).
Cytokines including interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α),
interleukin 17 (IL-17), and interleukin 2 (IL-2) are canonical cytokines for protection
against TB (18). Adjuvants investigated in TB vaccine clinical trials include toll-like
receptor 4 (TLR4) agonist GLA-SE, the two part liposomal adjuvant system CAF01, and
TLR4 agonist monophosphoryl lipid A (MPL) delivered with Q. saponaria fraction (QS21) in combination adjuvant system AS01 (16,19,20). These adjuvants have a common
goal of biasing the Th1/Th17 responses associated with strong cell-mediated immunity and
protection against pulmonary TB.
Recombinant Antigens for Subunit Tuberculosis Vaccines
Mtb expresses some 4000 proteins, many of which are expressed differentially
throughout the course of infection (17). This diversity poses significant challenge in the
selection of antigen for a subunit Mtb vaccine. Proteomic analysis of Mtb lysates among
infected individuals yield the most valuable insights into antigens which differentiate latent
and active Mtb infections (17,21). Systematic exposure of antigens to peripheral blood
mononuclear cells (PBMCs) sourced from Mtb infected individuals and subsequent
immunological assessment by T cell proliferative assays as well as interferon release assays
have allowed identification of which Mtb proteins have putative T cell epitopes capable of
4

provoking strong cell mediated immunity in vivo (22). Recombinant technologies afford
the opportunity to select multiple epitopes and join them into a singular fusion protein,
thereby accounting for heterogenous protein expression throughout infection. Several such
recombinant Mtb antigens have progressed to clinical trials for use in both TB preventatives
and therapeutics including H1, H4, H56, ID93, CysVac2, and M72 (23,24). These fusion
protein components and their clinically tested applications are detailed in Table 1.
Fusion Protein

Antigens

Vaccine Formulations

H56

Ag85B
ESAT6
RV2660

M72

Mtb39a
Mtb32a
Ag85B
ESAT6

H56:IC31
H56/CAF01
H56+K31
M72/AS01E

H1

H1:IC31

ID93

Rv1813
Rv2608
Rv3619
Rv3620
CysVac2
Ag85B
CysD
H4
Ag85B
TB10.4
Table 1: Clinically relevant TB fusion proteins

H1:CAF01
ID93+GLA-SE

CysVac2/Advax™
H4:IC31 (AERAS-404)

Though no work has been done to directly compare candidate fusion antigens, a
cross-study comparison of clinically evaluated Mtb vaccines analyzed efficacy across eight
in-human clinical trials as determined by antigen specific T cell memory responses.
Treatments investigated included the subunit vaccines H56:IC31, M72:AS01E, H1:IC31,
and ID93: GLA-SE, the viral vector vaccines AERAS-402 and MVA85A, as well as the
clinically licensed live-attenuated BCG. This comparison showed that while all clinical
candidates induced Th1 but not Th17 biased immunity, M72/AS01E cohorts showed the
5

most potent production of T cell memory (23). These data conclusively show that M72 as
a recombinant Mtb antigen is capable of provoking strong cell-mediated immunity in vivo.
The work detailed herein utilizes M72 fusion protein as a model antigen for the comparison
of T cell responses elicited by several adjuvant formulations in vivo.
T Cell Activation and Differentiation
T cells are adaptive immune cells which recognize antigens and are divided into
those which perform cytotoxic functions and those which perform immunomodulatory
functions (25). These two subsets can be distinguished by their cell surface markers CD8
and CD4, respectively. CD8-positive cytotoxic T lymphocytes (CTLs) recognize
intracellularly derived antigens presented through major histocompatibility complex I
(MHC I) to distinguish healthy cells from those infected with intracellular pathogens or
cancerous cells (26). CTLs direct the presenting cell to undergo apoptosis if the proteins
presented aren’t recognized as normal self-antigens, thereby limiting spread of infection.
CD4-positive T helper cells are further divided into subsets defined by their effector
cytokines and functions, and include regulatory T cells (Tregs), Th17, Th1, Th2, and T
follicular helper cells (TFH) (26). The many subsets of T helper cells are a direct reflection
of the diversity of pathogens they combat; the resulting toolkit allows for specialized
immunity against each type of threat. Table 2 summarizes the functions of major CD4 T
cell subsets and their indicators.
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Subset

T Reg

Polarizing

Transcription Effector

Cytokines

Factor

Cytokines

IL-2, IL-10,
FOXP3
TGF-β
IL-12, IFN-γ, T-Bet
IL-18, IL-27

IL-10, TGFβ
IFN-γ, TNFα

Th2

IL-2, IL-4,
IL-10, IL-25

GATA3

IL-4, IL-5,
IL-9, IL-13

Th17

IL-1, IL-6,
IL-23, TGFβ
IL-6, IL-21

RORγt

IL-17A,
IL17F, IL21, IL-22
IL-4, IL-21

Th1

TFH

Bcl-6

Effector Functions

Regulation and dampening
of immune responses
Intracellular immunity,
CTL and macrophage
activation, inflammation
Extracellular immunity,
antibody production,
allergy
Inflammation, intracellular
immunity
B cell help, antibody class
switching

Table 2: CD4+ T Cell Subsets and Their Defining Features
Naïve CD4+ T cells differentiate into the appropriate subtype during T cell
activation by antigen presenting cells (APCs). APCs are responsible for phagocytosis and
digestion of foreign bodies, and then presentation of foreign peptides to T cells for the
development of adaptive immunity (26). Naïve CD4+ T cells must recognize antigen
presented on major histocompatibility complex II (MHC II) as well as receive an activating
signal through CD28 to become mature antigen-specific effector cells (25). Cytokines
released by the APC during activation direct the T cell to commit to a master transcription
factor which will ultimately determine its effector subset. Figure 1 depicts antigen
recognition, co-stimulation of CD28, as well as the delineation of subsets based on the
polarizing cytokines released into the immune milieu during activation. CD4+ subsets are
defined for ease of explanation, although cells can express properties of multiple subsets
simultaneously and are not committed to a subset for life.
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Figure 1: CD4+ T Cell Activation and Differentiation. Figure created in Biorender.

Innate Immune Receptors and T Cell Polarization
The specific cytokines released during antigen presentation are dependent on
PAMPs recognized by the APC. PAMPs are motifs conserved across genres of pathogens
that inform innate immune cells of pathogen characteristics including cell wall components
or nucleic acid structure. For example, motifs distinct to viruses are recognized through
PRRs who’s downstream signaling induce cytokines that polarize Th1 biased immunity to
eliminate this perceived intracellular threat (26). In this way PRRs can tell T cells not just
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what the antigen looks like, but also what type of response will be most effective when the
antigen is encountered. Figure 2 briefly summarizes recognition of diverse pathogens
through PRRs and the downstream release of T cell polarizing cytokines for tailored
immune memory.
Figure 2: APC recognition of pathogen motifs through PRRs directs the production of T
cell polarizing cytokines. Figure created in BioRender.

Synthetic agonists targeting PRRs provide a novel opportunity for immune
therapeutics and vaccine adjuvants to direct cell-mediated immunity.
Toll Like Receptor 4 Agonists
TLR4 is a type I transmembrane glycolipid responsible for the detection of
damage associated molecular patterns and bacterial PAMP lipopolysaccharide (LPS).
TLR4 is primarily expressed on the cell surface where it signals through MyD88,
although following endocytosis TLR4 is able to signal through TRIF in a MyD88
9

independent fashion (27). Signaling through MyD88 results in the phosphorylation of
transcription factors AP-1, CREB, and NF-κB, which in turn induce production of proinflammatory cytokines as well as inflammasome activators. In contrast, activation
through TRIF results in downstream phosphorylation of IRF3 and IRF7 and the
production of type I interferons (IFNs) and chemokines (27). Figure 3 summarizes TLR4
signaling pathways and their outputs.
Figure 3: TLR4 Signaling Pathways. Figure created in BioRender.
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Multiple vaccines adjuvanted with TLR4 agonists have been licensed or reached
in-human clinical trials. Adjuvant System 04 (AS04), a two-part system composed of TLR
ligand MPL and aluminum salt, skews the immune response towards a Th1 bias with CD4+
T cells producing type I interferons, making it an effective adjuvant against intracellular
pathogens (28). Ceravix™ and Fendrix™ use AS04 to target human papillomavirus and
hepatitis B respectively, both of which require potent Th1 cell-mediated immunity for
protection. Adjuvant System 01 (AS01) similarly induces Th1 biased immunity through
immunostimulants MPL and QS-21 in a liposomal formulation, and is under investigation
in clinical trials for candidate malaria and is approved for Shingarix™ (29). MPL has been
characterized as biasing TRIF signaling, reducing toxicity compared to its parent
compound LPS for improved safety (30). Future TLR4 adjuvants may include synthetic
lipid A analogs with reduced fatty acid chains that maintain the safety profile of MPL,
however offer improvements to its solubility and stability (31). Our lab has previously
designed and characterized lipid A mimetics with improved toxicity/efficacy profiles
including the compound INI-2002 used herein (32,33).
Macrophage Inducible C-Type Lectin Receptor Agonists
Macrophage inducible C type lectin (Mincle) is a surface PRR present on select
APCs responsible for the recognition of mycobacterial cell wall carbohydrates. Mincle can
signal alone or as a homodimer with macrophage restricted C type lectin (MCL) with
whom it shares many ligands. Mincle/MCL signal through Syk to modulate transcription
via NFAT and NF-κB as illustrated in Figure 4 (34,35). Downstream induction of IL-6,
TNF, IL-1β, IL-12p70, and IL-23 make Mincle a potent mediator of Th1/Th17
polarization, making it an excellent clinical vaccine target.
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Figure 4: Mincle/MCL Signaling Pathway. Figure Created in BioRender

Other than the BCG vaccine itself, Freund’s Complete Adjuvant (FCA) was the
first vaccine or adjuvant system to contain Mincle agonists. A water in oil emulsion with
whole-cell killed Mycobacterium, CFA induced such potent Th1/Th17 immunity it later
became a tool used to induce and study both autoimmunity and chronic pain in vivo (36).
Mycobacterial cord factor, trehalose 6’6-dimycolate (TDM), was later identified as a
mycobacterial PAMP responsible for inducing potent Th1/Th17 responses through Mincle.
Synthetic TDM analogs designed for reduced toxicity have since been investigated as
candidate Th1/Th17 biasing adjuvants (37). Cationic formulation 01 (CAF01), a
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dimethyldioctadecylammonium (DDA) liposome formulated with cord factor analog
trehalose 6’6-dibehenate (TDB), has entered clinical trials for safety and efficacy as an
adjuvant for chlamydia as well as tuberculosis vaccines (20,38).
CAF01 provides a strong benchmark for future adjuvant design, however TDB’s
poor solubility and DDA’s instability leave room for improvement (39). Our group has
previously reported on the structure activity relationship of several classes of synthetic
trehalose analogs for the discovery of safe, effective, and easily formulated Th17 biasing
agonists (40,41). This work will detail the use of a novel unpublished synthetic trehalose
derivative UM-1098 selected based on inducing Th17 mediated immune responses
delivered in a stable silica nanoparticle (SNP) formulation.
Toll Like Receptor 4 Crosstalk with Macrophage Inducible C-Type Lectin Receptor
Scientists first discovered Mincle when the stimulation of macrophages with TLR4
ligand LPS induced transcription of its encoding gene Clec4e (42). Mincle has since been
characterized as minimally expressed unless induced by LPS, TNF-α, IL-6, or IFN-γ (43).
Mincle on the contrary is associated with the suppression of TLR4 signaling through
downregulation of co-receptor CD14 and thereby functions to limit TLR4 induced toxic
shock. (42,44). In this way Mincle and TLR4 provide checks and balances in innate
immune responses.
A novel DDA liposomal formulation combining MPL and TDB (DMT) has
demonstrated proof of concept for combination Mincle and TLR4 adjuvant systems
(45,46). DMT adjuvanted subunit vaccines were able to confer protection equal to or
greater than that of BCG as measured in TB challenge with H37Rv strain (46). Importantly,
DMT protected against reactivation of latent TB (46). DMT produced higher levels of IFN13

γ, IL-2, TNF-α, and IL-17A when compared with DDA-TDB and DDA-MPL formulations,
demonstrating the synergy between TDB and MPL components (45).
It should be noted that combination adjuvants are not limited to uses in vaccines.
Combination of ultra-pure LPS and TDB was recently noted to aid in restricting Mtb
infection when applied with isoniazid or rifampicin by means of induced autophagy (47).
Coadministration of adjuvants with antitubercular treatment not only enables dose sparing
of antibiotics, but also provides a novel approach to combatting drug resistant TB.
Adjuvant Delivery by Silica Nanoparticles
Delivery systems offer several advantages to therapeutics including stabilization of
conformation, prolonged antigen exposure, codelivery of antigen and adjuvant, as well as
potential for complex formation with multiple ligands (48,49). Dectin-1, a member of the
family of C type lectin receptors (CLRs), has demonstrated that binding of multiple
receptors is necessary for potent downstream signaling, suggesting that controlled coating
density on delivery vehicles could aid in complex formation and signaling in the CLR
family (50). Indeed, in the work detailed here we note that coating-density of Mincle
agonist UM-1098 on aminopropyl-SNPs (A-SNPs) drastically impacts immunogenicity in
a species-specific fashion.
Thesis Hypothesis and Project Rationale
Cell-mediated immunity is necessary for protection against intracellular pathogens
including the worldwide health threat tuberculosis, particularly Th1 and Th17 responses.
Both TLR4 and Mincle agonists have demonstrated their value in clinical trials as adjuvants
provoking Th1/Th17 cell-mediated immunity. Combination of TLR4 agonists (MPL or
ultra-pure LPS) and TDB has been demonstrated to provoke greater immunogenicity than
14

either agonist alone both in DDA based vaccines as well as in therapeutics. We have aimed
to reform this design through use of synthetic agonists with shorter lipid chains to both
increase solubility and decrease toxicity. TLR4 agonist INI-2002 and Mincle agonist UM1098 were selected for combination based on their induction of potent Th17 biased
immunity.
In lieu of DDA liposomes we have chosen to pursue SNPs as a rational delivery
mechanism with greater stability and feasibility in resource poor areas. The decision to use
SNPs was partially founded on the hypothesis that coating Mincle agonists onto SNPs
affords an opportunity to form multiple PRR-ligand complexes as previously demonstrated
with Dectin-1, with higher coating densities allowing for stronger signaling through
Mincle. To ensure that UM-1098 could form multiple complexes on a single cell, agonists
were adsorbed to silica independently and admixed.
Several molar ratios were investigated for the coadministration of UM-1098 and
INI-2002 in order to find where additive/synergistic responses occur as well as where they
were ablated. Given that both receptors are responsible for regulating each other’s
expression and signaling, we hypothesized finding an inflection point where negative
feedback would reduce innate cytokine production in vitro and thus decrease downstream
Th1/Th17 cell-mediated immunity. Based on previous in vivo dose selection data
suggesting that 50nmol/mouse and 1nmol/mouse doses were optimal for UM-1098 and
INI-2002 respectively, a 50 to 1 molar ratio was chosen as a logical starting point. The
overall hypothesis was that synergy would be observed at the molar ratio reflective of each
API’s optimal dose regimen, whereas straying from this molar ratio in either direction
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would diminish or eliminate synergy. The final selection of ratios for in vitro screening
ranged between 500:1 and 5:1 (UM-1098:INI-2002).
Indicators of innate synergy were chosen based on innate cytokines induced by each
PRR including IL-1β, TNF-α, and IL-6 being shared by both PRRs while RANTES was
chosen to distinguish the TRIF pathway of TLR4. Murine T cell responses following
vaccination were chosen as the main readout of adaptive synergy, with assessment of
intracellular cytokine production upon antigen restimulation as measured by flow
cytometry heavily prioritized, with IL-17 and IFN anticipated as primary synergistic
adaptive cytokines. This thesis was originally intended to include data following Mtb
challenge in mice vaccinated with a lead combination formulation, however the challenge
study was ongoing at the time of thesis submission and will be discussed in the future
directions section.
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CHAPTER 2: METHODOLOGY
Preparation of Compounds
INI-2002 was synthesized as previously described at Inimmune Corp. (32). UM1098 was synthesized by the Center for Translational Medicine medicinal chemistry team
at the University of Montana; and Asia Riel’s, Ph.D. write up on the synthesis of UM-1098
is detailed as follows. Reactions were monitored by TLC-analysis on Merck Silica gel 60
F254

plates

and

visualized

by

UV

at

254 nm

and

dipping

in

vanillin

(vanillin/water/ethanol/sulfuric acid, 0.2 g:5 mL:5 mL:1 mL) or phosphomolybdic acid in
ethanol (PMA) and developed with heat. Compounds were confirmed to be >95% pure by
NMR and HPLC-CAD analysis. 1H and 13C NMR spectra were recorded on an Agilent or
Bruker 400 MHz instrument and were referenced to TMS or a solvent peak. Highresolution HPLC-MS analysis was obtained on an Agilent 6520 Q-TOF mass spectrometer
utilizing an electrospray ionization source in positive or negative mode. Chromatography
was performed on Grace or Biotage automated medium pressure chromatography
instruments with preloaded Buchi silica gel cartridges. 2,2’,3,3’,4,4’-Hexa-O-benzoyl-α,αD-trehalose

and

2,2’,3,3’,4,4’-Hexa-O-benzoyl-6,6’-bis(methanesulfonayl)-α,α-D-

trehalose were prepared using the literature method without any modification (51).
BSA (140mL), followed by TBAF (4mL, 0.04 mmol) was added dropwise to a
solution of a,a-D-trehalose dihydate (25 g, 66 mmol) in dry DMF (100 mL). The reaction
mixture was stirred for 1 hr and then quenched with 2-propanol (25 mL). Reaction mixture
was frozen to -20 °C for 1 hr and then treated with a cooled solution of K2CO3 (9.1 g, 66
mmol) in 2000 mL of MeOH. After stirring for 10 min, the solution was neutralized with
acetic acid and then methanol was removed in vacuo. The resulting residue was extracted
17

with heptane and then the organic layer washed with brine and concentrated in vacuo to
produce a crude product. The purification of crude product was carried out by column
chromatography. 1H NMR (400 MHz, DMSO-d6) d 4.82 (d, J = 2.93 Hz, 1H), 4.58 (s,
1H), 3.81 - 3.89 (m, 1H), 3.69 (d, J = 10.51 Hz, 1H), 3.50 (d, J = 8.93 Hz, 2H), 3.40 (dd, J
= 3.06, 9.17 Hz, 1H), 3.33 (s, 1H), 0.03 - 0.16 (m, 27H); 13C NMR (100 MHz, DMSOd6) 93.5, 73.5, 73.3, 72.4, 71.0, 59.8, 1.1, 0.15.
To a stirred mixture of 2,2’,3,3’,4,4’-Hexa-trimethylsilyl-α,α-D-trehalose (1 eq.; 1
mmol), aryl carboxylic acid (2.2 eq.; 2.2 mmol) and DMAP (3 eq.; 3 mmol) in anhydrous
DCM (10 mL) was added DCC (3 eq.; 3 mmol) or EDCI-MeI (3 eq.; 3 mmol) at 0 °C for
30 min and then at room temperature overnight. The reaction mixture was diluted with
water and then extracted with DCM. The combined organic layer was dried over MgSO4
and reduced in vacuo. The crude mixture was subjected to chromatography using the
Biotage system with a 12 g silica column and a 0-20% ethyl acetate in heptane gradient.
This yielded the silyl intermediate in good to excellent yields.
The silyl intermediate (0.333 mmol) was dissolved in equal amount of methylene
chloride and methanol (8 mL) treated with Dowex 50WX8 resin (668.4 mg) with magnetic
stirring. Upon consumption of the starting material as determined by TLC (20% methanol
in methylene chloride and charring with vanillin stain) the reaction was filtered,
concentrated, and chromatographed on a silica column, followed by eluting with a 40-80%
methylene chloride to methanol gradient (Biotage system using a 12 g pre-packed column)
to provided desired product (63% for coupling and deprotection). 1H NMR (400 MHz,
DMSO-d6) d 7.13 (s, 4H), 5.17 (br, 2H), 4.98 (d, J= 8.9 Hz, , 4H), 4.85 (d, J= 4.4 Hz, 2H),
4.46 (d, J= 9.2 Hz, 2H), 4.14 (br, 2H), 4.04 (br, 2H), 3.84 (br, 12H), 3.64 (br, 2H), 3.28 (br,
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2H), 3.16 (br, 2H), 1.60 (br, 12H), 1.33 (br, 12H), 1.16 (br, 48H), 0.76 (br, 18H); 13C NMR
(100 MHz, DMSO-d6 165.17, 152.29, 141.39, 124.48, 107.13, 92.90, 72.71, 72.40, 71.67,
70.62, 69.70, 68.21, 64.48, 31.29, 31.22, 29.79, 28.88, 28.77, 28.76, 28.73, 25.59, 25.52,
22.08, 13.79, 13.76. HRMS: C28H28F6O13 NH4+ requires 1336.9237 Found 1336.9222.
Preparation of Formulations
A-SNPs formulations were prepared by Alexander Riffey in the Burkhart lab at the
University of Montana. A-SNPs were first prepared by modifying the surface chemistry of
silica nanoparticles (SNPs) purchased from nanoComposix, Inc. (Non-Functionalized
NanoXact Silica.) SNPs were washed from Type 1 ultrapure water into anhydrous ethanol
(EtOH) via centrifugation, then dried via rotary evaporation at 40°C. Dried SNPs were
weighed and transferred into a round bottom flask, where they were resuspended at 10
mg/mL in water for irrigation, USP (WFI) via bath sonication for approximately 30
minutes (37kHz, 20-30°C). The flask was charged with 0.105 µL (3-Aminopropyl)
triethoxysilane per mg of SNP and processed via bath sonication for 3 hours (37kHz, 70°C)
to modify the silica surface with aminopropyl moieties. After processing, the reaction flask
was magnetically stirred overnight at room temperature. ASNPs were recovered by
centrifugation and subsequently washed with 5 reaction volumes of WFI followed by 5
reaction volumes of EtOH, then dried via rotary evaporation at 40°C and stored at room
temperature.
Stock suspensions of A-SNPs were prepared in EtOH using bath sonication as
described for SNPs above. Stock solutions of the agonists UM-1098 and INI-2002 were
prepared by vortexing in THF:MeOH (9:1, v/v) and MeOH, respectively. Aliquots of the
A-SNP stock suspensions and the agonist stock solutions were transferred quantitatively
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into 2 mL round-bottom glass vials and mixed for 10 seconds before drying into a thin film
via speedvac vacuum concentrator until the vacuum reading reached approximately 300
mtorr (45°C heating for 1 hr, 2 hr run time, vacuum ramp 3.) After drying, sterile filtered
suspension vehicle was added to each sample vial immediately before processing. Sample
processing included bath sonication for 1 hr (37kHz, 55-65°C) followed by focused
sonication via Covaris S2 for 5 minutes (37°C, 10% duty cycle, intensity 8, 1000
cycles/burst in 15 second treatments for 20 cycles.) Samples were finally stored at 2-8°C
for 72 hr before use and characterization. Formulation characterization included DLS
particle sizing and zeta potential (Malvern ZEN 3600), sample pH, osmometry
(EliTechGroup VAPRO 5600), and total suspended agonist concentration via HPLC
(Waters Alliance 2695e with 2998 PDA detector.) Samples were vortexed at 3000rpm for
30 seconds immediately before use.
Formulation
Intended
Use

API

API
Concentration
(uM)

A-SNP
Size (nm)

SNP
Concentration
(mg/mL)

Solvent

In vivo/ In
vitro
In vitro

-

-

50

25

UM-1098

1000

200

10

In vivo

UM-1098

2500

50
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In vivo

UM-1098

1000

200

10

In vitro

INI-2002

820.5

50

10

2%
Glycerol
2%
Glycerol
2%
Glycerol
2%
Glycerol
WFI

In vivo

INI-2002

50

50
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Table 3: Formulation Details

20

2%
Glycerol

Prior to use in vivo, a stock of each injection condition was made and incubated on
a rotating mixer for an hour for adsorption of M72 antigen.
Isolation of Human PBMCs
Peripheral blood samples were collected from healthy adult donors. The samples
were collected after approval by the University of Montana Institutional Review Board
(43–16) and signed written informed consent was obtained from each donor. Peripheral
blood mononuclear cells (PBMC) were isolated from peripheral blood using Ficoll-Paque,.
Briefly, heparin-anticoagulated blood was diluted with an equal volume of Dulbecco’s
phosphate-buffered saline, pH 7.4 (DPBS), and 35 mL of diluted blood was layered over
15 mL of the Ficoll-Paque (Sigma). Gradients were centrifuged at 400×g for 30 min at
room temperature in a swinging-bucket rotor without the brake. The PBMC interface was
carefully removed by pipetting and washed with PBS-5%FBS followed by centrifugation
at 250×g for 10 min. This was followed by a second wash with PBS-5%FBS. Cells were
resuspended in RPMI medium with 5% autologous plasma. Cell number and viability were
determined using a hemocytometer. Non-viable cells were identified by trypan blue
staining and cell counts were calculated on viable cells only. Cells were added at
6x106 cells/well in RPMI with 5% autologous plasma to serially diluted formulations.
Supernatants were harvested from treated cells at 24 hr post-cell application.
Analysis of Cytokine Production
Supernatants from human PBMCs were analyzed using either a DuoSet ELISA
(R&D Systems, Minneapolis, MN) for human IL-6, TNF-α, IL-1β, or RANTES, or a
multiplex panel for analytes TNFα, IL-1β, IL-6, IFN-γ, IL-12p70 and IL-23 (MesoScale
Discovery) per the manufacturer’s instructions. Supernatants were serially diluted based
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on anticipated response. ELISAs were read on a SpectraMax® M5 Multi-Mode Microplate
Reader at 450 nm. Cytokine concentration was determined by fitting standard curve OD
values to a 4-parameter logistical model using curve fitting (XLFit, IDBS, Alameda, CA).
Supernatants from 72hr lymphocyte restimulation were analyzed using multiplex
panel for murine analytes IFN-γ, IL-5, and IL-17 (MesoScale Discovery) per the
manufacturer’s instructions. Supernatants were run neat. Plates were read on a MESO
QuickPlex SQ 120 instrument, and data were analyzed using Discovery Workbench
(MesoScale Discovery).
In Vivo Experiments
Animal studies were carried out in an OLAW and AAALAC accredited vivarium
in accordance with University of Montana's IACUC guidelines for the care and use of
laboratory animals. Groups of 8 C57BL/6 mice were vaccinated intramuscularly with 1 μg
M72 antigen and indicated concentrations of adjuvants candidates in 50 μl total volume
per injection. After 28 days, blood and serum samples were collected, and a secondary
vaccination was administered. At day 56 (28 days post-secondary vaccination), blood and
serum samples were collected, and a tertiary vaccination administered. At day 70 (14 days
post tertiary vaccination) mice were euthanized and blood was collected for the
measurement of M72-specific humoral immunity. Spleens and lymph nodes were collected
and homogenized for restimulation with antigen. Vaccination schedule and endpoints are
detailed in Figure 9.
ELISA for anti-M72 antibody quantification.
Sera were collected and diluted according to the expected antibody response
(between 1:10 and 1:5000). Plates were coated with 100 μl of the full-length M72 protein
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at 1 μg/mL. Following washing and blocking, plates were incubated with diluted serum for
1 hour followed by anti-mouse IgG, IgG1 or IgG2c-HRP secondary antibody (Bethyl
Laboratories) and TMB substrate (KPL). Plates were read at 450 nm. Antibody titers were
determined by fitting M72 specific positive control serum to a 4-parameter logistical model
using curve fit software (XLFit, IDBS, Alameda, CA).
Lymphocyte restimulation and cell-mediated immunity analysis.
Spleens and lymph nodes were harvested from vaccinated mice 14 days after
tertiary injections and lymphocytes were mechanically processed into a single cell
suspension. Red blood cells were lysed by incubation with red blood cell lysis buffer
(Sigma) for 5 min followed by washing in 1× PBS. Cells were plated in a 96 well plate at
5×106 cells/well in 200 μL complete RPMI1640 media and incubated with 1 μg/mL M72
antigen for either 6 hr or 72 hr at 37°C. Cells incubated for 72 hr were centrifuged and
supernatants were collected for cytokine production. Cells incubated for 6 hr were treated
with GolgiPlug (Brefeldin A, BD Biosciences) and incubated at 37°C for an additional 12
hr. Cells were then stained with the cell surface antibodies against CD3 BV605 (BD
Horizons, 17A2), CD4 APC-R700 (Biolegend, GK1.5) and CD8a APC-Cy7 (Biolegend,
53–6.7) and viability stain (Ghost 510, Tonbo Biosciences). Cells were treated with
cytofix/cytoperm (BD) and stained with anti-IFN-γ PE-CF594 (BD Biosciences,
XMG1.2), anti-IL2 FITC (Biolegend, JES6–5H4), anti-IL-5 PE (BD Pharm, TRFK5), antiIL-17A PerCP-Cy5.5 (Invitrogen, eBio17B7), and anti-TNFα PE-Cy7 (Biolegend, MP6XT22). Data was collected using an LSRII flow cytometer (BD) and analyzed using
FlowJo 10.0 software (TreeStar).
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Statistical Analysis
All statistical analyses were completed using GraphPad Prism 9.4.1. Nonlinear
least squares regression of human PBMC dose response curves with a four-parameter
variable slope was used to determine EC50 values and maximal cytokine output.
Confidence intervals were calculated asymmetrically, and unstable parameters were
identified and excluded. Best-fit values were compared using sum-of-squares F test.
Antibody titers from mouse sera, flow cytometry population statistics, and T cell
restimulation cytokines all were log transformed then subject to One-Way ANOVA with
Tukey’s post-hoc test.
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CHAPTER 3: RESULTS
In Vitro Stimulation of Human PBMCs
We first set out to assess the impact of API coating density and silica nanoparticle
size on UM-1098 potency. Coating density was tested in human PBMCs with normal
(200nm particles at 10mg/mL A-SNP to 1mM API, 50nm particles at 2.5mg/mL A-SNP to
1mM API) and 4x lower coating densities (200nm particles at 40mg/mL A-SNP to 1mM
API, 50nm particles at 10mg/mL A-SNP to 1mM API) comparing 50nm and 200nm ASNPs in N=1 donors. Dose responses were observed to be dependent on coating density
and independent of size. Coating densities of 200nm particles at 10mg/mL A-SNP to 1mM
API or their 50nm particle counterparts at 2.5mg/mL A-SNP to 1mM API showed a
superior UM-1098 dose response (Figure 5). Both assay performance and figure creation
are credited to Cassandra Buhl (Figure 5).
Figure 5: Coating density dependent responses of UM-1098 on A-SNPs. Legend
indicates starting concentrations of UM-1098 for each dose response curve. Figure
created by Cassandra Buhl.

hIL-6 (OD450)

4
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1
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To determine efficacy of UM-1098 and INI-2002 combinations in vitro, dose
response curves of UM-1098 and INI-2002 alone or combined in 50:1, 10:1, or 5:1 molar
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ratio favoring UM-1098 were characterized for production of IL-1β, TNF-α, IL-6, and
RANTES in human PBMCs with N=3 donors (* indicates where N=2). Figure 6 provides
a representative dose response for each cytokine profiled. Effective concentrations (EC50s)
and maximum effect (Emax) were determined for each formulation and compared for
significance using confidence intervals. UM-1098 was significantly less potent with a
higher EC50 than all other formulations for every cytokine analyzed (p<0.05). Significant
changes were not observed between EC50s for indicated cytokines in combination groups
over INI-2002 alone. No EC50 was able to be generated from the UM-1098 dose response
to TNF-α. Table 4 summarizes EC50 data.
IL-1β

TNF-α

IL-6

RANTES

EC50

CI95%

EC50

CI95%

EC50

CI95%

EC50

CI95%

(uM)

(uM)

(uM)

(uM)

(uM)

(uM)

(uM)

(uM)

UM-1098

6.995

N/A

N/A

1.955

N/A

N/A

N/A

INI-2002

0.08970

6.392 to
7.715
0.01880
to 1.609
0.04249
to
0.1425

0.01405

0.002936
to 0.06835
0.006439
to N/A

0.001930

0.0001861
to 0.007607
0.0002550
to 0.007658

0.004829*

0.0003185*
to 0.04897*
N/A

0.0008023
to 0.01268

0.004472*

0.0009055*
to 0.02074*

0.005130 to
2.871

N/A

N/A

0.08233
0.03795
0.002118
50nmol
UM-1098
: 10nmol
INI-2002
0.04739 0.01964
0.02217
0.006133
0.003790
50nmol
to
to 0.05780
UM-1098
0.09056
: 5nmol
INI-2002
0.05447 0.04185
0.05922 0.01917 to
0.01674
50nmol
to
2977
UM-1098
0.07449
: 1nmol
INI-2002
Table 4: Effective Concentrations in Human PBMCs. N=3,
N/A=not assessed
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N/A

* indicates where N=2.

Figure 6: Innate cytokine production in human PBMCs. N=3. Error bars represent SD.

Max cytokine production (Emax) of IL-1β, TNF-α, IL-6, and RANTES results are
tabulated in Table 5. IL-1β Emax was significantly increased in the 50:1 molar ratio group
in comparison to all other groups, with Emax of 18457pg/mL IL-1β (CI: 16885-20711).
TNF-α Emax was unable to be calculated for UM-1098.
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IL-1β

TNF-α

IL-6

RANTES

Emax

CI95%

Emax

CI95%

Emax

CI95%

Emax

CI95%

(pg/mL)

(pg/mL)

(pg/mL)

(pg/mL)

(pg/mL)

(pg/mL)

(pg/mL)

(pg/mL)

N/A

N/A

2821*

2360*
to
3682*
N/A

UM-1098

6001

INI-2002

12153

50nmol UM-1098
: 10nmol INI-2002

10045

50nmol UM-1098
: 5nmol INI-2002
50nmol UM-1098:
1nmol INI-2002

5759 to
6275
9511 to
21380

N/A

N/A

45207

23332 to
???
41025 to
61101

6222

5128 to
8349

50866

8815 to
11322

6361

5228 to
7526

59468

47040 to
72751

N/A

12085

10341 to
13962

6966

5932 to
8132

59570

50458 to
69177

2519*

18457

16885 to
20711

10959

8168 to
115266

80548

62770 to
212424

N/A

Table 5: Max cytokine output in human PBMCs. N=3, * indicates where N=2. N/A=not
assessed

Inhibitive capacity was visualized through the application of a constant
concentration of one active pharmaceutical ingredient (API) while the other was diluted in
a dose response in human PBMCs. Addition of 1µM UM-1098 to varying concentrations
of INI2002 did not result in reduced responses compared to 1µM UM-1098 alone among
IFNα2a, IL-6, TNFα, IL-1β, IL-23, or IL-6 (Figure 7). Addition of 0.01µM INI-2002 to
varying concentrations of UM-1098 was similarly performed and combination responses
did not result in reduced responses compared to 0.01µM INI-2002 (Figure 8). The same
experiment was completed with addition of 0.05µM INI-2002 to a UM-1098 dose response
curve, and combination resulted in diminished IL-23 responses when compared to 0.05µM
INI-2002 alone (Figure 9).
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2121*
to
3354*
N/A

Figure 7: Constant addition of 1µM UM-1098 to INI-2002 dose response in human
PBMCs. N=2.
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Figure 8: Constant addition of 0.01µM INI-2002 to UM-1098 dose response in human
PBMCs. N=2.
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Figure 9: Constant addition of 0.05µM INI-2002 to UM-1098 dose response in human
PBMCs. N=2.
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In Vivo Vaccination of C57BL/6 Mice Against M72: Humoral Immunity
C57BL/6 mice were vaccinated against M72 antigen every 28 days and harvested
14 days post-tertiary vaccination. The vaccination schedule is demonstrated in Figure 9,
and the vaccination conditions are tabulated in Table 6.
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Figure 10: In vivo study schedule and endpoints

Antigen specific antibody titers were assessed by M72 ELISA and detected using
IgG specific or IgG subclass specific antibodies. All mice receiving adjuvant produced
significantly greater M72 specific antibody titers than antigen only. There were no
observed differences in antibody responses between UM-1098 adsorbed to 50nm A-SNPs
and UM-1098 adsorbed to 200nm A-SNPs, indicating no size-dependent response. Postsecondary IgG1 was increased among combination groups over INI-2002 alone (Figure
11C). The 10nmol UM-1098 : 1nmol INI-2002 combination group had increased IgG1
production over 10nmol UM-1098 at the post-secondary time point, although the 50nmol
UM-1098 : 1nmol INI-2002 group did not have significantly increased titers over mice
receiving 50nmol UM-1098 (Figure 11C). Notably, UM-1098 had significantly higher
post-secondary IgG1 titers than INI-2002 (Figure 11C). All differences in IgG1 titers
among adjuvanted groups were washed out at the post-tertiary time point (Figure 12B). No
difference in antigen specific IgG2c titers was observed between adjuvanted groups at
either time point (Figure 11B, Figure 12C). When observing antigen specific IgG titers
without regard to serotype, both combination groups had increased IgG over INI-2002
treated mice but not over UM-1098 treated mice at the post-secondary time point (Figure
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11A). Post-tertiary antigen specific IgG in mice treated with the 50nmol UM1098 : 1nmol
INI-2002 combination was significantly higher than mice treated with UM-1098 alone but
not mice treated with INI-2002 alone (Figure 12A). Mice adjuvanted with 10nmol UM1098 and 1nmol INI-2002 had decreased IgG titers post-tertiary than when compared to
IgG titers from the same mice at the post-secondary time point. This assay was repeated
with similar results.
Description

# Mice

SNP Dose

UM-1098

INI-2002

M72 Dose

(ug)

Dose (nmol)

Dose (nmol)

(ug)

Naïve

6

-

-

-

-

A-SNP-50 Only

8

1000

-

-

-

Antigen Only

8

-

-

-

1

50nmol UM-1098-A-SNP-200

8

500

50

-

1

50nmol UM-1098-A-SNP-50

8

500

50

-

1

10nmol UM-1098-A-SNP-50

8

100

10

-

1

1nmol INI-2002-A-SNP-50

8

500

-

1

1

50nmol UM-1098-A-SNP-50 :

8

1000

50

1

1

8

600

50

1

1

1nmol INI-2002-A-SNP-50
10nmol UM-1098-A-SNP-50 :
1nmol INI-2002-A-SNP-50

Table 6: In vivo study conditions
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Figure 11: Post-secondary antibody titers. Asterisks indicate significance where *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001, # indicates antigen only group is significantly
different than all groups indicated under bracket where p<0.05. N=8

Figure 12. Post-tertiary antibody titers. Asterisks indicate significance where *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001, # indicates antigen only group is significantly
different than all groups indicated under bracket where p<0.05. N=8
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In Vivo Vaccination of C57BL/6 Mice Against M72: Cell-Mediated Immunity
Mouse lymph nodes and spleens were homogenized into single cell suspensions
then restimulated with antigen for determination of M72-specific T cell responses.
Restimulated cells were stained for CD3, CD4, CD8, IFN-γ, TNF-α, IL-2, IL-5, and IL-17
to be detected via flow cytometry. A representative gating strategy is depicted in Figure
13. Neither the lymphocytes from the lymph nodes (LN) or spleens displayed noticeable
changes in IL-5+ CD4+ T cells upon restimulation, even above that of antigen alone
(Figure 14 Panel C). Mice stimulated with 10nmol UM-1098 : 1nnol INI-2002 showed
significantly higher rates of TNF- α+ and IFN-γ+ CD4+ T cells in the lymph node when
compared to mice receiving UM-1098 only or the 50:1 molar ratio combination (Figure 14
Panel D and E). No significant differences were seen in IL-17+ T cells among adjuvanted
groups in the LN although all were significantly different than antigen only (Figure 14
Panel A). A trend towards more IL-17+ CD4+ splenocytes among combination adjuvants
was seen in comparison to mice adjuvanted with UM-1098-A-SNP-200 or given antigen
only. In comparing UM-1098 on 200nm SNPs vs 50nm SNPs, the only observable
difference was increased TNF-α producing cells in splenocytes treated with UM-1098 on
the 50nm size (Figure 14 Panel D). INI-2002 produced significantly more TNF- α+ and
IL-2+ antigen specific T cells in the spleen than UM-1098 counterparts (Figure 14 Panel
B and D).
Lymphocytes isolated from the spleens and lymph nodes were incubated with
antigen for 72hr and analyzed for adaptive T cell cytokines in cell supernatants. The 10:1
molar ratio combination was the most potent inducer of IFN-γ among all splenocyte
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supernatants and showed statistical significance above all other groups (Figure 15).
Production of IFN-γ in lymph node restimulation supernatants was significantly lower in
the 10nmol UM-1098 group than all other adjuvanted groups (Figure 15). IL-5 production
upon restimulation was not significantly different among any groups in spleen or lymph
node cultures above naïve or antigen stimulated groups (Figure 15). Secreted IL-17 in
lymph node restimulation supernatants was significantly higher in the 10:1 molar ratio
combination than either the 10nmol UM-1098 or 1nmol INI-2002 groups (Figure 15).
Splenocytes similarly had increased IL-17 recall in the 50:1 molar ratio combination in
comparison to UM-1098 groups (Figure 15).
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Figure 13: Representative T Cell Gating Strategy. Lymphocytes were gated for live dead
exclusion dye, followed by a singlet gate, a CD3 gate, and then for CD4 or CD8
phenotypes.

Cells

were

then
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intracellular
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Figure 14: Combination vaccination increases percentage of antigen specific CD4+ T Cells
Producing Th1 Biasing Cytokines. Intracellular cytokines IL-17a (A), IL-2 (B), IL-5 (C),
TNF-α (D), and IFN-ƴ (E) were measured via flow cytometry. Data represents percent of
total CD3+CD4+ population which produce indicated cytokine. Lines indicate means. Data
was log transformed and analyzed via one-way ANOVA with Tukey’s post-hoc test
(GraphPad Prism 9); asterisks indicate significance where *p<0.05, **p<0.01,
***p<0.001, # indicates antigen only group is significantly different than all groups
indicated under bracket where p<0.05. Asterisks indicate significance where *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001, # indicates antigen only group is significantly
different than all groups indicated under bracket where p<0.05. N=8
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Figure 15: Combination Vaccination Increases IL-17 and IFN-y Recall Upon Splenocyte

Restimulation. N=8. Asterisks indicate significance where *p<0.05, **p<0.01,

***p<0.001, ****p<0.0001.
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CHAPTER 4: DISCUSSION
The characterization of UM-1098 coated to A-SNPs in vitro successfully detected
several important properties to take into consideration when designing future formulations
of UM-1098 as well as other Mincle ligands. Coating density of UM-1098 on A-SNPs was
shown to be directly related to potency, which was determined to be independent of ASNP diameter (Figure 5). This finding supported the hypothesis that stabilization of Mincle
ligands on a silica nanoparticle enables UM-1098 to form multiple PRR-ligand interactions
for more potent signaling similar to the mechanism previously described with Dectin-1
(50). Comparisons of mice vaccinated against M72 antigen adjuvanted with UM-1098 on
50nm or 200nm A-SNPs found no significant difference in humoral adaptive immune
responses when dose of API and SNP were kept constant, further demonstrating that
signaling was independent of carrier particle size (Figures 11 and 12). In comparing the
cell-mediated immune responses to UM-1098 on 200nm SNPs vs 50nm SNPs, the only
observable difference was increased TNF-α+ CD4+ splenocytes treated with UM-1098 on
the 50nm size (Figure 14 Panel D). Though this difference may appear size dependent, it’s
important to note that the dose of both UM-1098 as well as A-SNP was held constant. The
same dose by weight of A-SNPs at a 50nm diameter has significantly more surface area
than the same dose by weight of 200nm diameter A-SNPs, meaning that the 50nm group
was at a lower coating density and observes the same trend as seen in vitro. Formation of
so-called “signalosomes” with Mincle ligands has not been published; further investigation
and understanding of this phenomenon would contribute significantly to adjuvant design.
Several clinically evaluated or licensed vaccines have been adjuvanted with
multiple PRR ligands for broader cell-mediated immune responses. Several of these
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combinations have utilized TLR4 agonist MPL including the M72/AS01E vaccine which
induced strong Th1 biased immunity. Although Mincle ligands including TDB have been
investigated clinically for their ability to induce Th17 responses, these agonists have yet to
be clinically tested in dual agonist vaccine formulations. Combination of Mincle and TLR4
agonists TDB and MPL respectively administered in DDA liposomes has been
demonstrated to increase production of IFN-γ, IL-2, TNF-α, and IL-17A in vivo. We
reformed this design with a rational approach to increased stability and safety while
minimizing toxicity. Adjuvants with shorter fatty acid chain lengths including INI-2002
and novel Mincle agonist UM-1098 were chosen, and SNPs were chosen as a carrier
molecule for controlled coating density and improved shelf life. When these combinations
were assessed in vitro, though combination of UM-1098 and INI-2002 did not significantly
change the EC50s of any cytokines assessed, synergy was observed in increased total IL1β output by 50:1 molar ratio combination (Figure 6). Increasing power by including more
donors may have increased statistical significance in Emax or EC50 among other
cytokines.
Working doses of the selected agonists were assessed for inhibitive capacity in vitro
to observe if Mincle-regulated suppression of TLR4 coreceptor CD14 would impact
efficacy. Inhibition of the UM-1098 dose response as measured by IFNα2a, IL-6, TNFα,
IL-1β, IL-23, and IL-6 was not observed following addition of a constant 0.01uM INI-2002
to each point of the UM-1098 dose curve (Figure 8). Interestingly, addition of 0.05uM
INI2002 to the UM-1098 dose response curve improved IL-23 over UM-1098 alone, but
cytokine production was lower than that of 0.05µM INI-2002 alone, indicating these
responses were less than additive (Figure 9). Addition of 1µM UM-1098 to INI-2002 dose
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response curves did not indicate anything less than additive responses (Figure 7). Overall,
these data suggest at least additive responses for all cytokines assessed other than IL-23
production, and it’s predicted that inhibition of other cytokines occurs at molar ratios
outside of the working range of the selected adjuvants.
Adaptive immune responses were assessed in vivo for both the characterization of
UM-1098 adsorbed to 50nm or 200nm A-SNPs as well as the characterization of
combinatorial administration of UM-1098 and INI-2002. Two combination groups were
investigated, one of which was based on previously determined optimal doses of each
compound (50nmol UM-1098 and 1nmol INI-2002) as well as a dose spared group with
the optimal dose of INI-2002 and a 5-fold reduction in UM-1098 dose (10nmol UM-1098
and 1nmol INI-2002). No difference was observed in humoral responses assessed by
antibody titers between UM-1098 administered at a fixed dose on 200nm or 50nm A-SNPs,
suggesting that responses were independent of carrier particle diameter (Figures 11 and
12). Post-secondary antibody responses showed that combination administration was able
to increase antigen specific IgG1 and IgG titers compared to those generated in singly
adjuvanted mice (Figure 11). These results were washed out in post-tertiary sera (Figure
12), however, it’s important to note that clinical vaccines rarely employ tertiary injections,
and the post-secondary sera are more representative of clinical efficacy. The increase in
IgG1 among dual-adjuvanted groups was unexpected; bias towards IgG1 is generally
associated with Th2 type responses. This finding is especially odd given that it conflicts
with T cell cytokine data which suggests a Th1 polarized response. Finally, the decrease in
post-tertiary IgG titers seen in the 10:1 molar ratio is likely a human error considering that
the same mice had notably higher titers only a month before. M72 specific antibody
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quantification was repeated on these samples with a new standard and similar results were
yielded. The ongoing Mtb challenge study will serve as a repetition to validate these data.
Further investigation into class switching as well as the analysis of antigen-specific IgA
responses would benefit understanding of humoral responses in Mincle and TLR4
combination groups.
Th1 and Th17 biased cell-mediated immunity is the strongest correlate of protection
against pulmonary tuberculosis. We hypothesized that combination of Th1/17 biasing
agonist INI-2002 with Th17 biasing agonist UM-1098 would yield potent Th1 and Th17
memory, and that Mincle signaling would be independent of carrier particle size.
Identification of cytokine producing antigen specific T cells via flow cytometry as well as
analysis of T cell cytokines following restimulation both indicated no changes in Th2
biasing cytokine IL-5 among any adjuvanted groups (Figures 14 and 15). In assessment of
Th1 associated cytokines we found that mice stimulated with the 10nmol UM-1098 : 1nmol
INI-2002 combination had the most TNF- α+ and IFN-γ+ CD4+ T cells as observed by
flow cytometry, with more potent responses than the 50nmol UM-1098 : 1nmol INI-2002
combination group (Figure 14 Panel D and E). Similarly, mice receiving the 10:1 molar
ratio combination produced the strongest IFN-γ recall among all splenocyte supernatants
and showed statistical significance above all other groups (Figure 15). Though no
differences in IL-17+ CD4+ T cells was seen among adjuvanted groups in the lymph nodes,
combination groups yielded increased numbers of IL-17+ CD4+ splenocytes in comparison
to UM-1098-A-SNP-200 and antigen only groups (Figure 14 Panel A). More promisingly,
secreted IL-17 in lymph node restimulation supernatants was significantly higher in the
10:1 molar ratio combination than either the 10nmol UM-1098 or 1nmol INI-2002 groups
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(Figure 15). Splenocytes similarly had increased IL-17 recall in the 50:1 molar ratio
combination in comparison to UM-1098 groups (Figure 15).
Taken together these data suggest the 10:1 molar ratio combination as the most
potent adjuvant formulation for Th1/Th17 biased immunity. This group was originally
designed with dose-sparing in mind, hypothesizing that through synergy this formulation
could do just as well as the 50nmol UM-1098 : 1 nmol INI-2002 combination group (as
determined by no statistically significant differences between the two groups). Instead, the
dose-spared group produced more potent Th1 responses than the group receiving a 50:1
molar ratio. It’s possible that Mincle dependent downregulation of TLR4 coreceptor CD14
partially reduced responses in the 50:1 molar ratio group. Analyzing expression profiles of
CD14 after combinatorial vaccination in vivo could more conclusively determine if higher
concentrations of Mincle are responsible for the partial ablation of synergy in adaptive
immune responses seen in the group receiving 50nmol UM-1098 : 1nmol INI-2002.
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CHAPTER 5: CONCLUSIONS
Summary of Findings
Mincle agonist UM-1098 signaling is dependent on coating density on the delivery
vehicle. Combination of TLR4 adjuvant INI-2002 and Mincle adjuvant UM-1098
delivered admixed on A-SNPs results in increased IL-1β secretion in vitro and produced
potent Th1/Th17 immune responses in vivo. Mincle and TLR4 were determined to work
additively at low doses for induction of innate cytokines IL-6, IL-1β, TNF-α, and IFNα2a,
but not for IL-23. Synergistic adaptive immune responses allowed for a five-fold reduction
in UM-1098 usage in vaccine formulations with as good or better responses than
combinations given at full dosage. Mice vaccinated against M72 and adjuvanted with
10nmol UM-1098 and 1nmol INI-2002 showed increased TNF- α+, IL-17+, and IFN-γ+
CD4+ T cells as observed by flow cytometry, as well as potent IFN-γ and IL-17 recall in
restimulation supernatants.
Future Directions
An ongoing murine Mtb challenge aims to compare previously characterized
10nmol UM-1098 : 1nmol INI-2002 combinations versus BCG. Outputs to be assessed
include IgG titers and subtypes, T cell restimulation responses, lung and spleen colony
forming unit counts, and histology of lungs post-challenge. Future in vivo studies will
include Mincle -/- and TLR4-/- mice from a C57BL/6 background to determine if synergy
is specific to Mincle and TLR4.
Stimulation of human PBMCs with UM-1098 or INI-2002 adsorbed to
fluorescently labeled silica nanoparticles followed by cell phenotyping and intracellular
cytokine staining will aid in understanding which cells are responsible for the synergistic
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innate immune response. Comparisons of INI-2002 and UM-1098 admixed versus coadsorbed to the same particle may also show enhanced responses, as has been demonstrated
for TLR4 and TLR7/8 agonists. Data for EC50 and Emax values will be expanded by
testing additional donors.
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